5HT2B / VASCULOPATHIES

Targeting 5HT2B Signaling to Address Vascular Disease

We’re advancing a next-generation, highly selective 5HT2B antagonist designed to modulate serotonin-driven vascular signaling.

By targeting a key pathway implicated in diseases such as systemic sclerosis (SSc) and pulmonary arterial hypertension, our approach aims to deliver safer, more precise therapies for conditions with significant unmet medical needs.

THE PROBLEM

Systemic Sclerosis (SSc) is a Vascular Disease

Many cases of SSc have primary heart Involvement (SSc-pHI), which is one of the leading causes of mortality in SSc. SSc-pHI is characterized by cardiac fibrosis, systolic and/or diastolic dysfunction, and arrhythmias.

SSc-pHI affects 7-39% of patients with SSc (about 100,000 people in the U.S.), mainly women aged 30–60. SSc causes chronic pain and disability, yet current treatments offer only symptomatic relief. There is a significant unmet need for therapies that prevent or reverse vascular damage, particularly in populations with SSc-pHI.

MARKET SIZE

Addressing a Large and Underserved Vascular Disease Market

WW / TAM

$ 0 B+

WW / SAM

$ 0 B+

US / SOM

$ 0 B+

THE STATISTICS

Incidence of vascular disease found among SSc patients

Renal Crisis

Pulmonary Arterial Hypertension (PAH)

Primary Heart Involvement (pHI)

Coronary Microvascular Disease

Digital Ulcers

Raynaud's Phenomenon

OUR SOLUTION

Our approach to the development of a 5HT2B antagonist:

Screening of a vast library using SAR, DMPK, and in vitro / in vivo selection.

Highly selective antagonist with required bioavailability.

Favorable toxicity results.

We are advancing our candidate through formulation.

PARTNER WITH SERO

Advancing New Therapies for Vascular Disease

Sero Pharmaceuticals is pursuing a targeted 5HT2B antagonist designed to address key signaling pathways in serious vascular conditions. We invite investors, researchers, and strategic partners to explore opportunities to collaborate.